• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Nkarta Inc.

    11/14/24 8:55:31 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NKTX alert in real time by email
    SC 13G/A 1 e664010_sc13ga-nkarta.htm

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

     

    (Amendment No. 1) *

     

    Nkarta, Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    65487U108

    (CUSIP Number)

     

    September 30, 2024 

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

         

    ☐  Rule 13d-1(b)

     

    ☒  Rule 13d-1(c)

     

    ☐  Rule 13d-1(d)

     

    (Page 1 of 9 Pages)

      

    __________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

         

    CUSIP No.

    65487U108

    13G Page 2 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Deerfield Mgmt, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    2,155,000 (1)

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    2,155,000 (1)

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,155,000 (1)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    3.05%

    12.

    TYPE OF REPORTING PERSON*

     

    PN

      __________________

    (1) Comprised of shares of common stock held by Deerfield Partners, L.P., of which Deerfield Mgmt, L.P. is the general partner.

        

    CUSIP No.

    65487U108 

    13G Page 3 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Deerfield Management Company, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    2,155,000 (2)

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    2,155,000 (2)

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,155,000 (2)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    3.05%

    12.

    TYPE OF REPORTING PERSON*

     

    PN

     __________________

    (2) Comprised of shares of common stock held by Deerfield Partners, L.P. of which Deerfield Management Company, L.P. is the investment advisor.

         

     

     

    CUSIP No.

    65487U108 

    13G Page 4 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Deerfield Partners, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    2,155,000

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    2,155,000

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,155,000

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    3.05%

    12.

    TYPE OF REPORTING PERSON*

     

    PN

     

     

     

     

    CUSIP No.

    65487U108 

    13G Page 5 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    James E. Flynn

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    2,155,000 (3)

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    2,155,000 (3)

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,155,000 (3)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    3.05%

    12.

    TYPE OF REPORTING PERSON*

     

    IN

     __________________

    (3) Comprised of shares of common stock held by Deerfield Partners, L.P.

        

    CUSIP No.

    65487U108 

    13G Page 6 of 9

     

    Item 1(a). Name of Issuer:
       
     

    Nkarta, Inc.

       
    Item 1(b). Address of Issuer's Principal Executive Offices:
       
     

    1150 Veterans Boulevard

    South San Francisco, CA 94080

       
    Item 2(a). Name of Person Filing:
       
     

    James E. Flynn, Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P.

       
    Item 2(b). Address of Principal Business Office, or if None, Residence:
       
     

    James E. Flynn, Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P., 345 Park Avenue South, 12th Floor, New York, NY 10010

       
    Item 2(c). Citizenship:
       
     

    Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P. - Delaware limited partnerships;

     

    James E. Flynn – United States citizen

       
    Item 2(d). Title of Class of Securities:
       
     

    Common Stock

       
    Item 2(e). CUSIP Number:
       
     

    65487U108

         
    Item 3.

    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

       
    (a) ☐

    Broker or dealer registered under Section 15 of the Exchange Act.

         
    (b) ☐ Bank as defined in Section 3(a)(6) of the Exchange Act.
         
    (c) ☐

    Insurance company as defined in Section 3(a)(19) of the Exchange Act.

         
    (d) ☐

    Investment company registered under Section 8 of the Investment Company Act.

         
    (e) ☐ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
         
    (f) ☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
         
    (g) ☐ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
       
    (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
         
    (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

    CUSIP No.

    65487U108 

    13G Page 7 of 9

     

    (j) ☐ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
         
    (k) ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ___________________________________________

     

    Item 4. Ownership.
           

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

           
    (a) Amount beneficially owned**:  
           
     

    Deerfield Mgmt, L.P. – 2,155,000 shares

    Deerfield Management Company, L.P. - 2,155,000 shares

    Deerfield Partners, L.P. - 2,155,000 shares

    James E. Flynn – 2,155,000 shares

           
    (b) Percent of class**:  
           
     

    Deerfield Mgmt, L.P. – 3.05%

    Deerfield Management Company, L.P. – 3.05%

    Deerfield Partners, L.P. – 3.05%

    James E. Flynn – 3.05%

           
    (c) Number of shares as to which such person has**:  
           
      (i) Sole power to vote or to direct the vote: All Reporting Persons - 0
           
      (ii) Shared power to vote or to direct the vote:

    Deerfield Mgmt, L.P. - 2,155,000

    Deerfield Management Company, L.P. - 2,155,000

    Deerfield Partners, L.P. - 2,155,000

    James E. Flynn – 2,155,000

           
      (iii)

    Sole power to dispose or to direct the disposition of:

    All Reporting Persons - 0
           
      (iv)

    Shared power to dispose or to direct the disposition of:

    Deerfield Mgmt, L.P. - 2,155,000

    Deerfield Management Company, L.P. - 2,155,000

    Deerfield Partners, L.P. - 2,155,000

    James E. Flynn – 2,155,000

      

    **See footnotes on cover pages which are incorporated by reference herein.

        

    CUSIP No.

    65487U108 

    13G Page 8 of 9

     

    Item 5. Ownership of Five Percent or Less of a Class.
       

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following ☒.

       
       
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

       
      N/A
       
    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

       

    If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

       
      N/A
       
    Item 8. Identification and Classification of Members of the Group.
       

    If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.

       
      See Exhibit B
       
    Item 9. Notice of Dissolution of Group.
       

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

       
      N/A

       
    Item 10. Certifications.
       

    "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a–11."

     

    CUSIP No.

    65487U108 

    13G Page 9 of 9

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    DEERFIELD MGMT, L.P.

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

    DEERFIELD MANAGEMENT COMPANY, L.P.

    By: Flynn Management LLC, General Partner

     

    By: /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

    DEERFIELD PARTNERS, L.P.

    By: Deerfield Mgmt, L.P., General Partner

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

    JAMES E. FLYNN

     

    /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

    Date: November 14, 2024

     

     

     

     

    Exhibit List

     

    Exhibit A. Joint Filing Agreement.
       
    Exhibit B. Item 8 Statement.
       
    Exhibit C. Power of Attorney (1).

     

    (1) Power of Attorney previously filed as Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P., Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P., Deerfield Management Company, L.P. and James E. Flynn.

     

     

     

     

    Exhibit A

     

    Joint Filing Agreement

     

    The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of Nkarta, Inc. shall be filed on behalf of the undersigned.

     

    DEERFIELD MGMT, L.P.

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

    DEERFIELD MANAGEMENT COMPANY, L.P.

    By: Flynn Management LLC, General Partner

     

    By: /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

    DEERFIELD PARTNERS, L.P.

    By: Deerfield Mgmt, L.P., General Partner

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

    JAMES E. FLYNN

     

    /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

     

     

     

    Exhibit B

     

    Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a “group” with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934.

     

    Get the next $NKTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NKTX

    DatePrice TargetRatingAnalyst
    10/9/2024$14.00Buy
    Rodman & Renshaw
    8/14/2024$16.00Outperform → Strong Buy
    Raymond James
    3/22/2024$13.00 → $16.00Strong Buy → Outperform
    Raymond James
    12/22/2022Outperform → Perform
    Oppenheimer
    10/10/2022$25.00Buy
    Canaccord Genuity
    7/28/2022$26.00Buy
    Needham
    7/18/2022$30.00Outperform
    SVB Leerink
    3/11/2022$17.00Outperform
    Raymond James
    More analyst ratings

    $NKTX
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Nkarta Inc.

      DEFA14A - Nkarta, Inc. (0001787400) (Filer)

      4/21/25 4:20:22 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Nkarta Inc.

      DEF 14A - Nkarta, Inc. (0001787400) (Filer)

      4/21/25 4:19:22 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Nkarta Inc.

      10-K - Nkarta, Inc. (0001787400) (Filer)

      3/26/25 4:20:11 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NKTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nkarta to Participate in an April Investor Conference

      SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: 24th Annual Needham Virtual Healthcare ConferenceApril 8, 202511:00 a.m. ET – fireside chat   A simultaneous webcast of the event will be available on the Investors section of Nkarta's website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmu

      4/1/25 8:01:00 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

      Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseasesInitial data for NKX019 in multiple autoimmune indications expected in second half of 2025Restructuring and workforce reduction of 34% (53 positions), including freezing of some future hires, to extend cash runway by more than one year to enable clinical milestones while having ample cash runway following the realization of those milestonesCash balance of $380.5 million on December 31, 2024, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWI

      3/26/25 4:01:00 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nkarta to Participate in March Investor Conferences

      SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences: TD Cowen 45th Annual Health Care ConferenceMarch 3, 20253:10 p.m. ET – fireside chat Leerink Partners 2025 Global Healthcare ConferenceMarch 10, 20253:00 p.m. ET – fireside chat A simultaneous webcast of the events will be available on the Investors section of Nkarta's website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company advancing the

      2/25/25 8:01:00 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NKTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ra Capital Management, L.P. bought $30,000,000 worth of shares (3,000,000 units at $10.00) (SEC Form 4)

      4 - Nkarta, Inc. (0001787400) (Issuer)

      3/29/24 5:38:04 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • George Simeon bought $20,000,000 worth of shares (2,000,000 units at $10.00) (SEC Form 4)

      4 - Nkarta, Inc. (0001787400) (Issuer)

      3/28/24 4:30:06 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NKTX
    Leadership Updates

    Live Leadership Updates

    See more

    $NKTX
    Financials

    Live finance-specific insights

    See more

    $NKTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

      SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing executive leadership responsibilities with Paul J. Hastings, who continues in his role as Chief Executive Officer. Additionally, Nkarta has broadened the role of David R. Shook, M.D., to Chief Medical Officer, Head of Research & Development. Drs. Mahmood and Shook will both report to Mr. Hastings. "This new leadership structure enables Nkarta to meet this transformative moment for cell therapy as

      7/16/24 6:01:00 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of

      5/15/24 4:05:00 PM ET
      $ENGN
      $NAMS
      $NKTX
      $PCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

      NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion regimenNKX019 clinical data presented at EHA 2023 and ICML 2023 meetingsClinical updates planned for NKX019 in the second half of 2023 and NKX101 in the first half of 2024Cash and cash equivalents of $302.2 million on June 30, 2023; cash runway anticipated to fund operations into 2025 SOUTH SAN FRANCISCO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter ended June 30, 2

      8/10/23 7:01:00 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

      New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy NKX019, an allogeneic CAR NK cell therapy targeting CD19+ B cells, could modify refractory autoimmune disease while maintaining NK-driven safety profile Off-the-shelf accessibility and proprietary engineering could eliminate burdens of autologous products and may enable differentiating conditioning regimen Resource prioritization and cost reductions expected to extend cash runway by one year into 2026 to support important clinical data readouts in 2024 Estimated cash and cash equivalents of $278.4 mil

      10/17/23 7:01:00 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

      SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will host a conference call on Tuesday, October 17, 2023 at 8:00 a.m. ET to discuss clinical program updates and organizational cost measures and resource prioritization to support clinical milestones. Conference Call and WebcastTo access the conference call, please register through this link: https://nkarta-business-update.open-exchange.net/registration A replay will be archived on the Investors section of Nkarta's website, www.nkartatx.com, for approximately four weeks. About NkartaNkart

      10/16/23 4:01:00 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

      Encouraging antileukemic activity seen with NKX101 in patients with AML, including several with high-risk features, using a modified lymphodepletion incorporating Ara-C (cytarabine)In patients with r/r AML treated with a three-dose regimen of NKX101 at 1.5 billion cells per dose after fludarabine/Ara-C for lymphodepletion, n=6 4 of 6 patients achieved complete response (67% CR/CRi, 50% CR rate)2 CRs with MRD negativity1 patient deepened response to MRD negative CRi with additional cycles NKX101 was well tolerated across dose-levels and lymphodepletion regimensExpansion cohort incorporating Ara-C based lymphodepletion expected to be the basis of NKX101 development moving forwardUpdated clinic

      6/27/23 7:01:00 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Shook David sold $19,004 worth of shares (8,638 units at $2.20), decreasing direct ownership by 4% to 190,955 units (SEC Form 4)

      4 - Nkarta, Inc. (0001787400) (Issuer)

      1/17/25 5:37:19 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Levin Alyssa sold $12,844 worth of shares (5,838 units at $2.20), decreasing direct ownership by 5% to 102,662 units (SEC Form 4)

      4 - Nkarta, Inc. (0001787400) (Issuer)

      1/17/25 5:36:57 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Technical Officer Brandenberger Ralph sold $16,383 worth of shares (7,447 units at $2.20), decreasing direct ownership by 6% to 124,796 units (SEC Form 4)

      4 - Nkarta, Inc. (0001787400) (Issuer)

      1/17/25 5:36:35 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NKTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Nkarta Inc.

      SC 13G - Nkarta, Inc. (0001787400) (Subject)

      12/13/24 5:02:47 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nkarta Inc.

      SC 13G/A - Nkarta, Inc. (0001787400) (Subject)

      11/14/24 4:05:12 PM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nkarta Inc.

      SC 13G/A - Nkarta, Inc. (0001787400) (Subject)

      11/14/24 8:55:31 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NKTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Nkarta with a new price target

      Rodman & Renshaw initiated coverage of Nkarta with a rating of Buy and set a new price target of $14.00

      10/9/24 7:55:21 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nkarta upgraded by Raymond James with a new price target

      Raymond James upgraded Nkarta from Outperform to Strong Buy and set a new price target of $16.00

      8/14/24 7:45:34 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nkarta downgraded by Raymond James with a new price target

      Raymond James downgraded Nkarta from Strong Buy to Outperform and set a new price target of $16.00 from $13.00 previously

      3/22/24 7:49:46 AM ET
      $NKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care